» Articles » PMID: 38355937

Oncoprotein SET-associated Transcription Factor ZBTB11 Triggers Lung Cancer Metastasis

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Feb 15
PMID 38355937
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is the major cause of lung cancer-related death, but the mechanisms governing lung tumor metastasis remain incompletely elucidated. SE translocation (SET) is overexpressed in lung tumors and correlates with unfavorable prognosis. Here we uncover SET-associated transcription factor, zinc finger and BTB domain-containing protein 11 (ZBTB11), as a prometastatic regulator in lung tumors. SET interacts and collaborates with ZBTB11 to promote lung cancer cell migration and invasion, primarily through SET-ZBTB11 complex-mediated transcriptional activation of matrix metalloproteinase-9 (MMP9). Additionally, by transcriptional repression of proline-rich Gla protein 2 (PRRG2), ZBTB11 links Yes-associated protein 1 (YAP1) activation to drive lung tumor metastasis independently of SET-ZBTB11 complex. Loss of ZBTB11 suppresses distal metastasis in a lung tumor mouse model. Overexpression of ZBTB11 is recapitulated in human metastatic lung tumors and correlates with diminished survival. Our study demonstrates ZBTB11 as a key metastatic regulator and reveals diverse mechanisms by which ZBTB11 modulates lung tumor metastasis.

Citing Articles

Epigenomic Echoes-Decoding Genomic and Epigenetic Instability to Distinguish Lung Cancer Types and Predict Relapse.

Baumann A, Buribayev Z, Wolkenhauer O, Salybekov A, Wolfien M Epigenomes. 2025; 9(1).

PMID: 39982247 PMC: 11843950. DOI: 10.3390/epigenomes9010005.


Enhanced ZBTB10 expression induced by betulinic acid inhibits gastric cancer progression by inactivating the ARRDC3/ITGB4/PI3K/AKT pathway.

Huang Z, Li Y, Zhao Z, Ye L, Zhang T, Yu Z Cell Oncol (Dordr). 2025; .

PMID: 39873948 DOI: 10.1007/s13402-025-01039-8.


Promoter Methylation as a Biomarker for Metastatic Risk in a Cohort of Non-Small Cell Lung Cancer Patients.

Thanou E, Lontra D, Balgouranidou I, Efthimiadou E, Delipetrou A, Tsaroucha E Biomolecules. 2025; 14(12.

PMID: 39766220 PMC: 11673096. DOI: 10.3390/biom14121514.


Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types.

Xu P, Zhang Q, Zhai J, Chen P, Deng X, Miao L Discov Oncol. 2024; 15(1):830.

PMID: 39715911 PMC: 11666857. DOI: 10.1007/s12672-024-01697-4.

References
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

2.
Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

3.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

4.
Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

5.
Wang D, Kon N, Lasso G, Jiang L, Leng W, Zhu W . Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature. 2016; 538(7623):118-122. PMC: 5333498. DOI: 10.1038/nature19759. View